WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006089309) METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/089309    International Application No.:    PCT/US2006/006951
Publication Date: 24.08.2006 International Filing Date: 15.02.2006
IPC:
A61K 31/44 (2006.01)
Applicants: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US) (For All Designated States Except US).
MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire En11 9BU (GB) (For All Designated States Except US).
FITZPATRICK, Shaun [GB/GB]; (GB) (For US Only).
SEILER, Christian [DE/GB]; (GB) (For US Only).
HARDY, Ian [GB/GB]; (GB) (For US Only).
WATERS, M., Gerard [US/US]; (US) (For US Only).
LAI, Eseng [US/US]; (US) (For US Only)
Inventors: FITZPATRICK, Shaun; (GB).
SEILER, Christian; (GB).
HARDY, Ian; (GB).
WATERS, M., Gerard; (US).
LAI, Eseng; (US)
Common
Representative:
MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US)
Priority Data:
60/654,703 17.02.2005 US
Title (EN) METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS
(FR) METHODE DE TRAITEMENT DE L'ATHEROSCLEROSE, DE DYSLIPIDEMIES ET DE TROUBLES LIES
Abstract: front page image
(EN)A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.
(FR)L'invention concerne une méthode de traitement de l'athérosclérose, au cours de laquelle de l'acide nicotinique ou un autre agoniste du récepteur de l'acide nicotinique est administré à un patient en combinaison avec un antagoniste du récepteur DP. Cet antagoniste du récepteur DP est administré de manière à diminuer, prévenir ou éliminer des bouffées vasomotrices qui peuvent se produire autrement.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)